JPRN-UMIN000012725招募中未知
Phase II study of neoadjuvant erlotinib in patients with stage III-N2 non-small cell lung cancer with EGFR mutations - Phase II study of neoadjuvant erlotinib in patients with stage III-N2 non-small cell lung cancer with EGFR mutations
Department of Thoracic Surgery, Tsukuba University Hospital0 个研究点目标入组 15 人开始时间: 2014年1月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active lung disease such as interstitial pneumonia, pneumoconiosis, radiation pneumonitis, or medicine-induced pneumonitis 2) Prior exposure to agents directed at the HER axis (e.g. erlotinib, gefetinib, cetuximab, trastuzumab) 3) Gastrointestinal abnormalities, including active peptic ulcer or inflammatory bowel disease 4) Active ophthalmologic diseases (e.g. Sjogrens) 5) Neurological symptoms of spinal cord compression 6) Uncontrolled infections 7) History of severe heart disease 8) Serious medical complications 9) Multiple primary cancer 10) Serious psychiatric illness or psychological symptom 11) Women who are pregnant, lactating or with childbearing potential 12) Ineligible based on decision of an investigator.
研究者
相似试验
已完成
2 期
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43
已完成
2 期
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32
已完成
2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54